Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series
ConclusionsThe cases discussed highlight the utility in 40-GEP to provide additional information to guide treatment decisions and improve outcomes. Integrating novel molecular prognostication with traditional clinicopathological risk factors can improve stratification of high-risk cSCC patients and may inform selection of risk-appropriate treatment and surveillance strategies.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Cancer & Oncology | Carcinoma | Dermatology | Genetics | Skin | Skin Cancer | Squamous Cell Carcinoma